The IMI Scientific Research Agenda  is a multiannual research plan, setting out the research priorities of IMI.  The priorities defined in the Research Agenda are the basis for the research topics of the annual Calls for proposals. Scientific advances and changes in the industry led the IMI Scientific Committee to initiate in 2010 the revision of the original (2008) SRA . The process included consultation of stakeholders and resulted in a revised SRA in 2011. A fact sheet on the revised SRA is available as well.

The IMI Research Agenda builds on the recommendations in the earlier Strategic Research Agenda to overcome the principle causes of delay in pharmaceutical R&D by focusing on four areas:

• Predicting safety: more accurately evaluating the safety of a compound during the pre-clinical phase of the development process and the later phases in clinical development.
• Predicting efficacy: improving the ability to predict how a drug will interact in humans and how it may produce a change in function.
• Knowledge management: more effective utilisation of information and data for predicting safety and efficacy.
• Education and training: closing existing training gaps in the drug development process.

Both knowledge management and education & training aim, as underpinning areas, to improve the information flow between the different phases of the drug development process.

The Research Agenda has been approved by the IMI Governing Board at its meeting on 3 March 2008.

It is the role of the IMI Scientific Committee to advise on the continued relevance of the Research Agenda and recommend any amendments.